Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia (OP-724-H201)
Sponsor: Kiminori Kimura, MD
Summary
This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.
Official title: A Multi-center, Single-arm, Open-label Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia
Key Details
Gender
MALE
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2024-05-08
Completion Date
2026-03-31
Last Updated
2025-03-17
Healthy Volunteers
No
Conditions
Interventions
Foscenvivint
Administered by intravenous (IV) infusion over 3-4 hours
Locations (3)
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
National Hospital Organization Osaka National Hospital
Osaka, Osaka, Japan
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, Japan